Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus in Healthy Subjects Following Two Single Subcutaneous Doses

Trial Profile

Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus in Healthy Subjects Following Two Single Subcutaneous Doses

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Jun 2014 Primary endpoint of maximum Serum LY2963016 or Lantus Concentration (Cmax) has not been met according to results presented at the 74th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2014 Primary endpoint of Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-) has been met, according to results presented at the 74th Annual Scientific Sessions of the American Diabetes Association.
    • 28 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top